Skip to main content
Evidence Snapshot

C-X-C chemokine receptor type 4

CHEMBL2107 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2107
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C-X-C chemokine receptor type 4 as ChEMBL target CHEMBL2107, mapped to UniProt P61073. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C-X-C chemokine receptor type 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2107
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P61073
C-X-C chemokine receptor type 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why C-X-C chemokine receptor type 4 matters

As of 2026-09-13

C-X-C chemokine receptor type 4 is reviewed as C-X-C chemokine receptor type 4 (UniProt P61073); C-X-C chemokine receptor type 4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 1853 compounds, and 549 assays, with lead potency reaching pChEMBL 10.7.

Disease context
neoplasm

C-X-C chemokine receptor type 4 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BALIXAFORTIDE, MAVORIXAFOR, MOTIXAFORTIDE.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BALIXAFORTIDE, MAVORIXAFOR, MOTIXAFORTIDE, MSX-122. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 1853 compounds, and 549 assays for this target. The dominant activity type is IC50. CHEMBL4751485 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL4751485 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why C-X-C chemokine receptor type 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P61073, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1853
Total Compounds
549
Total Assays
6
Approved Drugs
IC50: 1550.0, KI: 140.0, EC50: 300.0, KD: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4751485
 10.7 IC50 —
No preferred name
CHEMBL5612607
 9.9 EC50 —
No preferred name
CHEMBL5611972
 9.7 EC50 —
No preferred name
CHEMBL5612623
 9.7 EC50 —
No preferred name
CHEMBL5613902
 9.6 EC50 —

Approved Drugs

Structure Compound First Approval
MAVORIXAFOR
CHEMBL518924
 2024
PLERIXAFOR
CHEMBL18442
 2008
ZALCITABINE
CHEMBL853
 1992
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2107